HUAKANG(SH:605077) Shang Hai Zheng Quan Bao·2025-11-28 19:03Core Viewpoint - Zhejiang Huakang Pharmaceutical Co., Ltd. has announced the termination of its major asset restructuring plan, which involved the issuance of shares and cash payment to acquire 100% of Henan Yuxin Sugar Alcohol Co., Ltd. This decision was made after careful consideration of the prolonged transaction timeline and changes in the market environment [8][13][20]. Group 1: Announcement Details - The company will hold an investor briefing on December 8, 2025, to discuss the termination of the major asset restructuring and answer common investor questions [2][5][17]. - Investors can submit questions until December 5, 2025, through the Shanghai Stock Exchange Roadshow Center or via the company's email [2][7]. Group 2: Meeting Information - The investor briefing will take place online from 11:00 AM to 12:00 PM on December 8, 2025, at the Shanghai Stock Exchange Roadshow Center [5][6]. - Key participants in the meeting will include the company's chairman, general manager, financial officer, board secretary, and independent director [4]. Group 3: Transaction Termination Reasons - The decision to terminate the transaction was based on significant changes in the market environment since the initial planning phase, which prompted the company to prioritize the interests of its investors [13][20]. - The board of directors unanimously approved the termination of the asset acquisition and the withdrawal of the application documents during a meeting held on November 28, 2025 [20][21]. Group 4: Impact of Termination - The termination of the transaction is not expected to have a significant adverse effect on the company's operational and financial status, and it does not harm the interests of the company or its minority shareholders [15]. - The company has committed to not planning any major asset restructuring for at least one month following the announcement [16].